RxDoctor Payments Data

Esteffany Medina Rutledge, MD

Family Medicine · Waipahu, HINPI 1215424569

Payments from drug & device makers

$1,222in general payments, 2019–2025

Across 64 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$361
  • AstraZeneca$225
  • Novo Nordisk$156
  • Boehringer Ingelheim$142
  • Lilly USA, LLC$128
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • plus $83 from 5 others

What the payments were for

  • Food & beverage$1,222100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,222 in reported general payments places this provider in the 75th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$34,336
Medicare patients
142
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide55$96,524
JardianceEmpagliflozin47$54,386
MounjaroTirzepatide39$48,725
FarxigaDapagliflozin Propanediol43$35,297
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$29,726
EliquisApixaban20$23,686
JanuviaSitagliptin Phosphate11$17,212
MyrbetriqMirabegron13$14,347
Atorvastatin Calcium363$4,003
Dexlansoprazole DrDexlansoprazole13$3,342
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,155
Gabapentin143$2,559
Levothyroxine Sodium240$2,548
Losartan Potassium176$2,257
Albuterol Sulfate HfaAlbuterol Sulfate68$2,091

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$156$96,52455 claims
Boehringer IngelheimJardiance$142$54,38647 claims
Lilly USA, LLCMounjaro$128$48,72539 claims
AstraZenecaFarxiga$225$35,29743 claims
GSKTrelegy Ellipta$17$29,72625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Waipahu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →